



Vaccinomics: Omics-System Biology Approach in Vaccine Development

Guest Editors:

Dr. Vijay Soni

Weill Department of Medicine,
Weill Cornell Medical College,
New York, NY 10022, USA

Dr. Yogesh Chawla

Mayo Clinic, Rochester, MN, USA

Deadline for manuscript
submissions:

closed (1 July 2024)

Message from the Guest Editors

In last 3 years we have seen the power of omics for the COVID-19 vaccine development. Different types of omics are adding great values to solve diseases and find better cures. Omics technologies include genomics, transcriptomics, proteomics, metabolomics, and immunomics. These technologies have been used in vaccine research, which can be summarized using the term “vaccinomics.” These omics technologies combined with advanced bioinformatics analysis form the core of “systems vaccinology.” Omics technologies provide powerful methods in vaccine target identification. The genomics-based reverse vaccinology starts with predicting vaccine protein candidates through in silico bioinformatics analysis of genome sequences. Systematic transcriptomics and proteomics analyses facilitate rational vaccine target identification by detecting genome-wide gene expression profiles. Immunomics is the study of the set of antigens recognized by host immune systems and has also been used for efficient vaccine target prediction. Therefore, we are pleased to invite you to contribute high-quality original research articles, reviews and communications on the special issue.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)